VectorY Therapeutics, an Amsterdam-based biotech company developing vectorised antibody therapies for neurodegenerative diseases, has completed a €74.5 million Series B financing round. The capital injection brings together support from a broad coalition of new and established investors, signalling confidence in the company’s novel therapeutic approach.
The round includes participation from Angelini Ventures, Invest-NL, the European Investment Bank (EIB), Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BGV, Eli Lilly and Company, and the ALS Investment Fund. This diverse investor base reflects both the financial sector’s interest in neurodegenerative disease treatments and the backing of major pharmaceutical players.
Advancing the Lead Programme
VectorY will deploy the newly raised capital to push forward its most advanced candidate, VTx-002, which is currently being evaluated in the PIONEER-ALS Phase 1/2 clinical study. The expanded trial will provide crucial data on the therapy’s potential to address amyotrophic lateral sclerosis, a rapidly progressive neurodegenerative condition with limited treatment options. Alongside this primary focus, the company plans to develop VTx-003, a candidate targeting Huntington’s disease, and continue early-stage work on additional pre-clinical programmes.
“We believe VectorY is building a compelling approach to one of the most challenging areas of medicine. Its progress with VTx-002, including the expansion of the PIONEER-ALS study, is an important step in evaluating the program’s potential,” said Wouter Joustra, General Partner at Forbion.
Vectorised Antibodies as Treatment Strategy
Founded in 2020, VectorY represents an emerging category of biotech companies exploring vectorised antibodies—a platform designed to deliver therapeutic antibodies across the blood-brain barrier, a significant challenge in treating central nervous system diseases. This approach potentially addresses a critical bottleneck in neurodegenerative disease treatment, where many promising compounds fail to reach affected brain tissue effectively.
The company’s focus on ALS and Huntington’s disease reflects areas of substantial unmet medical need. While ALS remains rapidly progressive with few approved therapies, Huntington’s disease currently lacks disease-modifying treatments altogether. The involvement of the ALS Investment Fund among the backers underscores the sector’s commitment to addressing this particular indication.
European Biotech Momentum
The financing demonstrates the continued strength of European biotech fundraising, particularly in neurodegenerative disease research. VectorY’s ability to attract both specialised life sciences investors and major pharmaceutical backing illustrates how European companies tackling intractable neurological conditions are drawing international attention. The participation of institutions like the EIB, which supports innovation across the continent, reflects broader EU policy priorities around advancing healthcare innovation.
With this Series B capital, VectorY joins a growing cohort of European biotechs advancing beyond preclinical stages into human trials, positioning the region as a significant player in regenerative and neurological medicine development.